BioNTech and Bristol Myers Squibb join forces for new key therapy in immuno-oncology

The focus is currently on several solid tumour types, including non-small cell and small cell lung cancer as well as triple-negative breast cancer. The first phase 3 trials with potential regulatory relevance are already underway, with more planned for 2025. The companies are aiming for joint development both as a monotherapy and in combination with other active substances. The development of new indications also remains part of the strategy. The agreement includes equal profit and loss sharing. BMS will initially make an upfront payment of USD 1.5 billion and plans to make further payments of up to USD 2 billion by 2028. BioNTech can also look forward to success-based milestone payments of up to USD 7.6 billion. Both partners see BNT327 as a potential key therapy in immuno-oncology with broad applicability. The combination of two mechanisms of action in one molecule could set new standards in the treatment of difficult-to-treat tumours and complement or replace existing checkpoint inhibitors. The collaboration combines scientific excellence and global market access with the aim of enabling patients to benefit from innovative therapies at an early stage.